What question did this study set out to answer?

This research investigates the significance of PDLIM2 in lung adenocarcinoma and its potential for targeted therapy.

August 10, 2026British Journal of CancerOpen Access

Exploring PDLIM2 as a prognostic biomarker and therapeutic target in lung adenocarcinoma

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial explores PDLIM2's role in lung adenocarcinoma, suggesting its potential as a therapeutic target.

This research investigates the significance of PDLIM2 in lung adenocarcinoma and its potential for targeted therapy.
Next-generation sequencing and immunohistochemistry were performed on lung adenocarcinoma tissues from 15,765 patients.
PDLIM2 gene therapy was tested in LUAD mouse models using intravenous nano-complexed plasmid DNA, with or without chemoimmunotherapy.
Tumors with high PDLIM2 were found more in primary biopsies than in metastatic samples (73.1% vs 53.0%, p < 0.001).
High PDLIM2 expression correlated with lower mutation rates in several genes but increased EGFR mutations (all p < 0.01).
Preclinically, PDLIM2-based therapy improved median overall survival in mice compared to chemoimmunotherapy alone (10-12.5 vs 8-9 days; p = 0.0001, 0.0003).

Ashouri et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark